Trial Profile
A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTERODINE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2020
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms EIGHT
- Sponsors Pfizer
- 26 Jul 2020 Results of pooled analysis from two placebo-controlled trials of fesoterodine over 12 weeks in group of men and women with overactive bladder over 65 years presented at the 35th Congress of the European Association of Urology
- 31 Aug 2018 Results (n=6689) of pooled analysis from 6 studies (A0221008, A0221012, A0221013, A0221046, A0221094, A0221095) characterising patient symptom response resented at the 48th Annual Meeting of the International Continence Society
- 31 Aug 2018 Results (n=6689) of pooled analysis from 6 studies (A0221008, A0221012, A0221013, A0221046, A0221094, A0221095) examining efficacy and safety presented at the 48th Annual Meeting of the International Continence Society